TG Therapeutics Inc (FRA:NKB2)
€ 15.464 0.042 (0.27%) Market Cap: 2.38 Bil Enterprise Value: 2.29 Bil PE Ratio: 75.23 PB Ratio: 15.97 GF Score: 73/100

TG Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 02:00PM GMT
Release Date Price: €31.65 (+0.86%)
Dylan Gering
Raymond James Financial - Analyst

Great, I'll kick this off. Raymond James is pleased to have TG Therapeutics present at the 2021 Human Health and Innovation Conference. From the Company, we have Michael Weiss, Executive Chairman, President and Chief Executive Officer. And with that, I'll turn this over to you, Michael, for the presentation.

Michael Weiss
TG Therapeutics, Inc. - Executive Chairman, President & CEO

Okay. Thanks. I appreciate it. Thanks, everyone, for joining us. Let me just share my screen here, which hopefully shouldn't be too challenging. Okay, hopefully this is -- lets you slide in. Okay, all right. So again, thanks, Raymond James, for having us today. And I will be making some forward-looking statements. So, for those who are interested, I do encourage you to review our public disclosure documents available on the Internet.

So, okay, perfect. So, by the way, just a quick way of background, Company was founded in 2012 with the goal to develop novel treatment options for patients with B-cell diseases. Those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot